Managing director at Northwest Technology Ventures, an Oregon seed fund focused on technology-based startups and spinouts.
These startups are from the research sector in both life sciences and technology. NTV’s seed funding has provided the leverage for the companies in NTV’s investment portfolio to raise a cumulative investment of over $200 million to date, advancing businesses through growth stages into manufacturing, sales, and profitability. Representative current investments in technology include Adapx, which has developed the middleware platform to enable handwritten and forms input for GIS, CAD, and other enterprise applications, and Advanced Inquiry, which has developed a full-wafer test solution for the semiconductor industry. Investments in the life sciences include Clinicient, the leading provider of software and billing services for revenue cycle management in the physical rehab sector, and Artielle Immunotherapeutics, with an immunomodulatory platform based on recombinant receptor ligands, now in preparation for Phase II clinicals. Bill spent over a decade as a scientist at the Massachusetts Institute of Technology where he directed a joint program with the Harvard Medical School to develop and evaluate technology for the treatment of cancer. His discoveries led to four patents, and he left MIT to found a start-up based on this research. Following this experience he subsequently entered the venture industry to focus on early-stage investments, launching NTV in 2002. He serves on numerous corporate boards within the NTV portfolio, as well as on various academic and civic boards including past chair